Articles
Study Results

Can Retatrutide Cause Thyroid Cancer? What the Trials Show

Where the thyroid C-cell tumor warning on GLP-1-based medicines comes from, what retatrutide's published trials reported about thyroid cancer, and what is still unknown.

Written By
retaweightloss.com
Updated on
11 Nov 2026
Time to read
5 min read
Category
Study Results
Retatrutide and thyroid cancer risk

Can Retatrutide Cause Thyroid Cancer? What the Trials Show

Where the thyroid C-cell tumor warning on GLP-1-based medicines comes from, what retatrutide's published trials reported about thyroid cancer, and what is still unknown.

By
RetaWeightLoss.com
Created on:
15 Jul 2026
Updated on:
11 Nov 2026
Share this post

Does Retatrutide Cause Thyroid Cancer? The Short Answer

There is no evidence that it does, and not enough evidence to rule it out. Neither the 48-week Phase 2 obesity trial of 338 people nor the 80-week Phase 3 TRIUMPH-1 trial of 2,339 people reported any case of medullary thyroid cancer, the type linked to the warning on GLP-1-based medicines, or of C-cell hyperplasia. TRIUMPH-1 reported two cases of thyroid cancer of other types, one on 4 mg and one on 12 mg, and none on placebo. Numbers this small cannot show whether the drug raises the risk; rare cancers can take longer to appear and need far larger numbers of people to detect.

Retatrutide is investigational and has no approved label, so it has no official warning of its own yet. Approved medicines that act on the same GLP-1 receptor, such as tirzepatide and orforglipron, carry a boxed warning about the risk of thyroid C-cell tumors.

Where the Thyroid Warning Comes From

The US label for tirzepatide, which acts on two of the same receptors as retatrutide, is an example. Its boxed warning, based on rodent findings with GLP-1 receptor agonists, says that in rats, tirzepatide causes thyroid C-cell tumors, and that it is unknown whether it causes such tumors, including medullary thyroid carcinoma (MTC), in humans, because the human relevance of the rat findings has not been determined. The label describes the rat tumors as dose-dependent and treatment-duration-dependent at clinically relevant exposures.

The label lists two contraindications linked to this warning: a personal or family history of MTC, and multiple endocrine neoplasia syndrome type 2 (MEN 2), a genetic condition that raises the risk of MTC. It also notes that routine monitoring of calcitonin, a blood marker of C-cell activity, or thyroid ultrasound is of uncertain value for early detection.

MTC starts in the thyroid's C-cells and is different from the more common types of thyroid cancer. Orforglipron carries the same boxed warning as a class warning, even though its label says it is not pharmacologically active in rats or mice and did not produce tumors in rodents.

What Retatrutide's Trials Reported

The 48-week Phase 2 obesity trial of 338 participants, published in the New England Journal of Medicine in 2023, reported no cases of medullary thyroid cancer or C-cell hyperplasia.

The Phase 3 TRIUMPH-1 paper, published in the same journal in September 2026, covers 80 weeks of treatment in 2,339 adults with obesity, or overweight with a weight-related condition, and without diabetes. Its safety table counts thyroid cancer and C-cell hyperplasia together; calcitonin comes from the supplementary appendix:

TRIUMPH-1, 80 weeks 4 mg (584) 9 mg (583) 12 mg (582) Placebo (586)
Thyroid cancer or C-cell hyperplasia, participants 1 (0.2%) 0 1 (0.2%) 0
Calcitonin, change from start to week 80 +14.5% +14.6% +11.6% −1.9%


The thyroid row is from Table 3 of the paper; the calcitonin row is from Table S12 of its supplementary appendix and shows model-based estimates. The paper states that there were no cases of medullary thyroid cancer or C-cell hyperplasia, so the two cases in the first row were thyroid cancers of other types; the paper does not say which. With two cases among 1,749 participants on retatrutide and none among 586 on placebo, the trial cannot show whether the difference is due to the drug.

Calcitonin, the blood marker of C-cell activity, rose by about 12% to 15% on retatrutide and changed little on placebo (−1.9%), according to model-based estimates in the paper's supplementary appendix. Average levels stayed low, at 1.4 to 1.5 ng/L at week 80, against upper limits of normal of 7.6 ng/L for women and 14.3 ng/L for men given in the same table. The tirzepatide label states that the value of routine calcitonin monitoring for early detection of MTC in people taking tirzepatide is uncertain.

TRIUMPH-1 also excluded people at higher risk: anyone with a personal or family history of MTC or MEN 2, and anyone whose calcitonin at screening was 20 ng/L or more (35 ng/L or more if their eGFR was below 60). Its other reported effects are in retatrutide side effects.

Why the Trials Cannot Settle the Question

MTC is rare. A trial of a few thousand people followed for up to about two years is far too small and short to detect a small increase in a rare cancer, or to rule one out. Evidence on that kind of risk usually comes from long-term follow-up and large safety databases after a medicine is approved. For retatrutide, that evidence does not yet exist.

We found no published animal carcinogenicity results for retatrutide, so it is not publicly known whether it produces the rat thyroid findings seen with GLP-1 receptor agonists.

What Is Still Unknown

  • Whether retatrutide causes thyroid C-cell tumors in animals or in people.
  • What warnings and contraindications a retatrutide label would carry if it were approved.
  • Long-term cancer rates beyond the trials published so far (see retatrutide long-term safety).

Lilly plans to submit retatrutide to the US Food and Drug Administration in the first quarter of 2027.

Sources

  • Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. Published September 29, 2026. DOI: 10.1056/NEJMoa2604169. Updated October 22, 2026; Table 3 and Supplementary Appendix (exclusion criteria, Table S12). (TRIUMPH-1)
  • Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526.
  • Eli Lilly. US prescribing information for tirzepatide for weight reduction: boxed warning, sections 4 and 5. Revised August 2026.
  • Eli Lilly. US prescribing information for orforglipron tablets: boxed warning. 2026.
  • Eli Lilly. What to know about retatrutide.
  • Eli Lilly. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C. July 23, 2026.

Medical Disclaimer: This article is for informational purposes only and is not medical advice. Retatrutide is investigational and is not approved by the FDA for any use. It is not available by prescription, and Lilly says no one can legally sell it for human use. The figures described here are those reported in clinical trials under medical supervision.

Frequently asked questions

Does retatrutide cause thyroid cancer?

There is no evidence that it does, but not enough evidence to rule it out. Neither the Phase 2 obesity trial nor the Phase 3 TRIUMPH-1 trial reported medullary thyroid cancer, the type linked to the warning on GLP-1-based medicines, or C-cell hyperplasia. TRIUMPH-1 reported two thyroid cancers of other types on retatrutide and none on placebo, too few to show an effect. Trials lasting up to about two years are too small and short to rule out a small increase in a rare cancer.

Why do GLP-1 medicines have a thyroid cancer warning?

Because of rodent findings with GLP-1 receptor agonists. The US label for tirzepatide, for example, says it caused thyroid C-cell tumors in rats and that it is unknown whether it causes such tumors, including medullary thyroid carcinoma, in humans. Most GLP-1-based medicines carry the warning as a class warning.

Were there thyroid cancers in the retatrutide trials?

The 48-week Phase 2 obesity trial of 338 people reported no medullary thyroid cancer and no C-cell hyperplasia. In the 80-week Phase 3 TRIUMPH-1 trial, thyroid cancer was reported in 2 of 1,749 participants on retatrutide, one on 4 mg and one on 12 mg, and in none of 586 on placebo; neither case was medullary thyroid cancer. Neither trial was designed to measure cancer risk.

Will retatrutide have a thyroid warning?

That is not yet known. Retatrutide is not approved and has no label. Approved GLP-1-based medicines such as tirzepatide and orforglipron carry a boxed warning about thyroid C-cell tumors, but a retatrutide label would be decided by regulators if it is approved.

Newsletter

Stay Updated on New Articles & Research

Get notified when we publish new articles, research, and insights on obesity and weight loss.
You're subscribed!
You'll get new coverage as it's published.
Oops! Something went wrong while submitting the form.